Our goal is to bring better care & quality of life to patients wherever they are
Images courtesy of Dr Toby Garrood, Guy’s Hospital, London
99mTc-maraciclatide - A novel imaging agent under investigation for endometriosis and inflammatory arthritis
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Its goal is to bring to market effective tools to accelerate diagnosis and to deliver earlier and more effective treatment decisions for patients.
Its radio-labelled imaging agent, 99mTc-maraciclatide, is being developed to underpin personalised medicine primarily in the fields of endometriosis and inflammatory arthritis. 99mTc-maraciclatide binds to the αvβ3 integrin which is crucial to the development of new blood vessels, a key feature of both conditions. Clinical trials with world-leading academic partners are underway in both these indications.99mTc-maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
Seracam® - A revolutionary high resolution hybrid gamma-optical camera for point-of-care imaging
Serac Imaging Systems is a medtech company and developer of Seracam.
Seracam incorporates cutting-edge technology into a miniaturised, cost-effective, high resolution gamma camera with real time optical video image fusion. It has been designed as a highly versatile and compact alternative to traditional fixed nuclear medicine cameras, to enable molecular imaging procedures at the patient bedside, and also improve workflow in the nuclear medicine department. Seracam is currently being evaluated in a number of clinical settings. Seracam is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.
